Does tirzepatide reduce LV mass and paracardiac adipose tissue in patients with obesity-related HFpEF?
In patients with obesity-related HFpEF, tirzepatide reduces LV mass and paracardiac adipose tissue, providing a potential physiologic mechanism for the clinical benefits seen in the main SUMMIT trial.
The CMR substudy of the SUMMIT trial demonstrated that tirzepatide therapy in obesity-related HFpEF led to reduced LV mass and paracardiac adipose tissue as compared with placebo, and the change in LV mass paralleled weight loss. These physiologic changes may contribute to the reduction in heart failure events seen in the main SUMMIT trial. (A Study of Tirzepatide LY3298176 in Participants With Heart Failure With Preserved Ejection Fraction HFpEF and Obesity: The SUMMIT Trial; NCT04847557).
Kramer et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: